Compare Figs Inc (FIGS) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs IDEXX Laboratories, Inc. — how do they compare? Figs Inc trades at $15.58 (market cap $2.49B), while IDEXX Laboratories, Inc. trades at $519.96 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 16.2× Figs Inc's market cap, and Figs Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| FIGS | IDXX | |
|---|---|---|
Market Cap | $2.49B | $40.43B |
Volume | 5,964,311 | 692,164 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $766.68 |
52-Week Low | $6.90 | $504.70 |
Typical Hold Time | 33 Days | 46 Days |
Enterprise Value | $2.25B | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS stock trades at $15.78, up 12.23% over the past day, reflecting strong momentum. The technical outlook is bullish, supported by moving averages, while recent earnings beats and raised 2026 guidance highlight fundamental strength. Revenue growth accelerated to 28.8% in Q2 2026, with international sales surging 67%, and the company maintains a high gross margin of 68.91%.
The investment outlook is positive, with a consensus price target of $18.00 implying 14% upside. However, risks include a rich valuation (P/E of 45.39) and execution challenges in sustaining growth. Analyst sentiment is predominantly bullish, with 60% recommending buy, but investors should monitor margin pressures and competitive dynamics.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
